Latest Medical Devices News

Universal Biosensors Pty Limited has entered voluntary administration with KPMG appointed as administrators, signaling urgent financial distress and a potential restructuring ahead.

ReNerve Limited has achieved a key milestone with its first sale and clinical use of a deep dermal tissue product in the US, broadening its surgical applications beyond nerve repair. This move complements its existing nerve repair portfolio and sets the stage for further product launches later this year.

Audeara Limited reports a strong start to FY26 with a 46% revenue increase driven by Australian wholesale growth and a key international partnership. The company’s global ambitions are further highlighted by multiple export award nominations.

ResMed Inc has updated the foreign exchange rate for its forthcoming dividend payable to ASX-listed CDIs, setting the Australian dollar payout at 9.24 cents per CDI. This adjustment reflects the latest USD to AUD exchange rate and carries important tax implications for investors.

EMVision Medical Devices has been awarded a $3 million non-dilutive government grant to conduct a pioneering clinical study using its telehealth-enabled emu™ brain scanner in regional South Australia, aiming to transform stroke diagnosis and treatment.

Cochlear Limited has extended its on-market share buy-back program, allowing the company to repurchase up to AUD 75 million of its fully paid ordinary shares until August 2026.

Cochlear Limited reported a solid FY25 with 4% revenue growth and a 1% rise in underlying profit, underpinned by new product launches and expanding evidence linking implants to reduced dementia risk. The company’s FY26 outlook signals further gains as it advances market leadership and innovation.

Cochlear Limited reported a 4% revenue rise in FY25, driven by strong implant sales and launched the world’s first smart cochlear implant system. The company forecasts up to 17% profit growth in FY26, underpinned by innovation and expanding markets.

Cochlear Limited has reported steady financial growth with a 4% rise in sales revenue and a 9% increase in underlying net profit for the fiscal year ending June 2025, maintaining its dividend payout.

Atomo Diagnostics has successfully placed $416,611.77 from its Share Purchase Plan shortfall, bolstered by a recent US order from Lumos Diagnostics. This capital injection strengthens Atomo’s position as it scales up production of its Pascal cassettes.

Vitasora Health has expanded its partnership with Tampa Family Health Centers to deliver chronic care and remote monitoring services to 7,000 Medicaid patients, unlocking over US$4 million in annual revenue. This marks a pioneering step for Florida’s largest Federally Qualified Health Center in adopting value-based care for underserved communities.

EBR Systems has secured FDA approval for its pioneering leadless WiSE CRT System and obtained key Medicare reimbursement endorsements, setting the stage for its commercial rollout. The company also completed a significant capital raise to support its market expansion.